Company intelligence / Profile preview

Invivyd

Waltham, Massachusetts, United States

Ownership: Public · IVVD
Employees: ~125
Development stage: NDA

Overview

Invivyd’s lead product PEMGARDA™ (pemivibart) received Emergency Use Authorization from the US FDA in March 2024 for pre-exposure prophylaxis of COVID‑19 in certain immunocompromised patients. The company continues to develop next-generation antibody candidates using its INVYMAB™ platform. VYD2311 entered Phase 1 trials in August 2024. Adintrevimab completed trials but EUA filing depends on variant susceptibility. Early-stage programs target influenza and other high-priority viruses[1][3][4].

Therapeutic areas: Infectious Diseases
Modalities: Monoclonal antibodies (mAbs)
Industry: Biotech

Drug pipeline

8 assets

VYD2311

7 more assets in the full pipeline.

Request access →

Partnerships

Long-term agreement with a contract manufacturing organization for clinical/commercial supply; seeking commercial partnerships and collaborations with universities/academic medical centers/biopharma companies[2][3].

Financials

Market cap: $234.9M
Total revenue: $14.3M
Enterprise value: $83.2M

Beyond the preview

Go deeper on Invivyd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Invivyd.

Explore the full profile